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Editorial
The FREEDOM Study: does the Saga 
Continue for Diabetic Patients?
Marinella Centemero1, Alexandre Abizaid2, J. Eduardo Sousa3
T he FREEDOM study, recently presented at American Heart Association (AHA) congress in November 2012 and simultaneously published in the presti­
gious New England Journal of Medicine, demonstrated 
that myocardial revascularisation surgery provides better 
results than percutaneous coronary intervention (PCI) with 
drug­eluting stents (DES) for the treatment of diabetic 
patients with complex coronary artery disease. In this 
international multicenter study involving 140 hospitals, 
of which four are located in Brazil (Instituto Dante 
Pazzanese de Cardiologia – São Paulo, SP; Instituto 
do Coração do Hospital das Clínicas da Faculdade de 
Medicina da Universidade de São Paulo – São Paulo, 
SP; Hospital Universitário da Pontifícia Universidade 
Católica de Porto Alegre – Porto Alegre, RS; and Hospital 
Cardiológico Costantini – Curitiba, PR), 1,900 diabetic 
patients with multivessel involvement and no lesions 
in the left main coronary artery were randomized to 
coronary artery bypass graft (CABG) surgery or PCI 
procedures.1
At the end of the five­year follow­up (mean follow­up 
of 3.8 years), the primary study outcome, consisting of 
death from all causes, non­fatal myocardial infarction, 
and non­fatal stroke, occurred in 26.6% of the PCI/
DES group vs. 18.7% in the CABG group (P = 0.005), 
with a relative risk reduction of 30% in favor of CABG. 
Surgical revascularisation was also associated with 
lower rates of myocardial infarction (6% vs. 13.9%, 
P < 0.001), but with a significantly higher incidence 
of stroke (5.2% vs. 2.4%; P = 0.03). There was also 
a marginal reduction of overall mortality in patients 
treated with CABG when compared to PCI/DES (10.9% 
vs. 16.3%; P = 0.049). 
Whether these results will have an impact on clinical 
practice and how they will influence future guidelines 
for the treatment of coronary heart disease in diabetic 
individuals remains to be determined.
The publication of this important study follows 
a series of previous studies regarding the question of 
the best available treatment for the management 
of patients with coronary artery disease and diabetes. 
This saga began in the 1990s with the first study, “By­
pass Angioplasty Revascularization Investigation” (BARI), 
which warned the scientific community about the clinical 
and anatomical complexity of this subgroup and the 
great challenges that PCI (at that time characterized by 
the balloon angioplasty) represented for these patients. 
These challenges included incomplete revascularisation 
due to the difficulty of approaching certain types of 
lesions, such as total occlusions, and the high rates of 
coronary restenosis.2 These factors, together with the 
high cardiovascular risk inherent to diabetes patients, 
compromised the late clinical outcome and resulted in 
higher mortality in the percutaneous group. Interestingly, 
in patients with diabetes who were eligible for the study 
but were not randomized (BARI registry), for whom the 
best treatment strategy was decided by the physicians 
on an individual basis, there was no difference in 
mortality between the two types of revascularisation.3 
Subsequently, during the nearly 20­year period fol­
lowing the published alert from National Heart, Lung, 
and Blood Institute (NHBLI) in September 1995,4 based 
on the results of BARI, several randomized trials, meta­
analyses, and cohort studies analyzed the performance 
of diabetic patients treated by CABG or PCI, with and 
without the use of DES, in the context of multivessel 
coronary disease. Among them, two recent randomized 
studies should be highlighted: Coronary Artery Revascu­
larization in Diabetes (CARDia) and SYNergy Between 
PCI With TAXUS and Cardiac Surgery (SYNTAX).5,6
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In the CARDia study, 510 diabetic patients with 
multivessel disease or complex single­vessel disease 
were randomized to receive PCI (sirolimus­DES were 
used in 70% of the patients) or CABG. After five years, 
the occurrences of the combined outcome of death, 
myocardial infarction, and stroke were similar in both 
groups (26.6% vs. 20.5%; P = 0.11).
However, the rates of death, myocardial infarction, 
stroke, and the need for a second revascularization were 
significantly higher in the PCI group (37.5% vs. 26%, 
P = 0.005), leading the authors to conclude that the 
performance of percutaneous treatment in this subgroup 
was feasible and safe, although new interventions are 
necessary.5
In the SYNTAX study, which included 1,800 pa­
tients with complex coronary artery disease randomized 
to CABG or PCI/DES (paclitaxel), 452 patients were 
diabetics (25%), with higher­risk clinical profiles com­
pared to non­diabetics (significantly higher percentage 
of women, arterial hypertension, dyslipidaemia, heart 
failure, peripheral vascular disease, and previous stroke). 
Nevertheless, the incidence of major events (death, 
myocardial infarction, and stroke) was similar in the 
CABG and PCI groups at the end of one­year6 (10.3% 
vs. 10.1%, P  =  0.96) and three­year7 (16.3% vs. 14%; 
P = 0.53) follow­ups. New procedures were significantly 
more frequent in diabetics treated with PCI/DES, both 
after one year (20.3% vs. 6.4%; P < 0.001) and three 
years of evolution (28% vs. 12.9%; P = 0.001). 
In summary, the CARDia and SYNTAX studies, which 
involved almost 1,000 diabetic patients, demonstrated 
that percutaneous treatment (in most cases with the 
use of DES) is as safe as CABG, since the combined 
rates of major adverse cardiac events were similar with 
the two techniques. Both studies also demonstrated 
that CABG surgery has the advantage of a decreased 
need for interventions in the short­ and medium­term 
compared to PCI. This fact is probably related to the 
greater anatomical complexity of the lesions treated in 
diabetic patients, which consequently result in higher 
rates of restenosis and incomplete revascularization, 
even with the use of DES. The accelerated progression of 
coronary atherosclerosis is also a contributing factor to 
the need for repeat revascularizations in this subgroup. 
Upon detailed analysis of the FREEDOM study, 
several virtues can be identified:
 1. It was the first randomized, multicenter study spe­
cifically designed to evaluate both types of revas­
cularization (percutaneous vs. surgical) exclusively 
in diabetic patients with complex coronary artery 
disease.
 2. Both CABG and PCI were performed according to 
contemporary practice available at the time (2005­
2010).
 3. It was a superiority trial, which provides great 
statistical value.
 4. It was sponsored by an independent institution of 
unquestionable prestige (NHLBI).
 5. To date, the study has involved the largest number 
of patients with a confirmed diabetes diagnosis 
(1,900), randomized for the comparison of the two 
types of revascularisation.
 6. The majority of patients (approximately two­thirds) 
had triple vessel disease.
 7. There was great concern regarding the control 
of risk factors related to coronary artery disease, 
particularly diabetes, emphasizing the achievement 
of stringent goals established by the international 
guidelines of cardiology and the American Diabetes 
Association (ADA). 
However, as for all studies, even those carefully 
designed to fit in the canons of evidence­based medi­
cine, critical analysis can and should be performed. 
Therefore, the following considerations regarding the 
FREEDOM trial aim to exercise clinical reasoning, dra­
wing upon the experience gained during the many years 
of daily practice since the beginning of interventional 
cardiology, as well as active participation in several 
randomized studies. 
It is noteworthy that approximately 33,000 diabetic 
patients were screened to participate in the survey, 
but only 10% (3,309) were eligible, of whom 1,900 
(57%) agreed to fully participate in the study. Thus, 
their conclusions refer specifically to this population. 
There is no information regarding the treatment given 
to the diabetics excluded from the study or to those 
who refused randomization, although eligible. A “FREE­
DOM registry” showing the revascularization technique 
employed and the evolution of these patients, similar 
to what the SYNTAX and BARI studies showed, would 
be desirable and enlightening.
Throughout the five­year recruitment period, the 
study was amended twice – in 2007 and 2009 – with 
regard to sample size, duration of clinical follow­up, 
and the rate of major cardiovascular events, probably 
due to the long randomization time (2005­2010) and the 
low rate of patient recruitment. Initially, 2,400 diabetic 
patients were predicted to be enrolled during a two­year 
period, with a minimum follow­up of three years, to 
ensure 85% power to detect a relative reduction in the 
primary endpoint of 18% to 23% after four years. The 
study ended with 1,900 patients who were followed for 
4.75 years, with a minimum follow­up of two years and 
an estimated power of 80% to detect a 27% relative 
reduction in event rates for the two treatment groups. 
Regarding the results, it is noteworthy that the 
mortality of diabetic patients undergoing CABG surgery 
at 30 days in the FREEDOM trial was only 1.7%, an 
extremely low percentage that is most likely difficult to 
reproduce in daily practice outside of the ideal condi­
tions of a randomized study.
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Accordingly, we cite the Brazilian experience, well 
documented by Braile and Gomes,8 which reveals that 
the average mortality for Coronary artery bypass graft 
(CABG) surgery in Brazil, based on data provided by 
the Department of Informatics of the Brazilian Unified 
Health System (Banco de Dados do Sistema Único de 
Saúde – DATASUS), is approximately 4.8%. In Europe, 
these rates vary from 3% to 7.3%.
In another article, published in 2009, that collected 
data on the Brazilian experience on CABG from the 
database of the Hospital Information System of the 
Sistema de Informações Hospitalares do Sistema Único 
de Saúde (SIH/SUS) from 2005 to 2007, Piegas et al.9 
reported that 63,529 procedures were performed in 191 
hospitals. The overall in­hospital mortality was 6.2%, 
and it was higher in hospitals with lower surgical vol­
ume when compared to that observed in larger­volume 
hospitals (7.29% vs. 5.77%, P <0.001). Comparatively, 
these authors cited data from the American registry 
“Adult Cardiac Surgery in New York State” 2003­2005, 
which observed a 30­day mortality rate of 2.14%. The 
authors also cited the mortality rates of the member 
countries of the project “European System for Cardiac 
design Operative Risk Evaluation (EuroSCORE).” These 
rates were as follows: Germany, 2.4%; United Kingdom, 
3.7%; Spain, 6.8%; Italy, 2.4%; France, 3.2%; and 
Finland, 1.5% (mean of 3.4%).9 
Another interesting finding concerns the analysis 
of the combined primary endpoint of the study accord­
ing to several pre­specified subgroups. Outside of the 
United States, the occurrence of major cardiac events 
at five years was similar for PCI/DES and CABG (25% 
vs. 21%, P = NS). The explanation for this regional 
difference remains unclear. 
 After such considerations, it appears that there is 
no consensus regarding the best option for multivessel 
revascularization in diabetic patients. Revascularization 
strategies should be individualized according to other 
variables, such as patient fragility, risk of stroke, presence 
of comorbidities (such as kidney disease and chronic 
obstructive pulmonary disease), experience of the in­
terventional and surgical teams, patient socioeconomic 
status, and adherence to pharmacological treatment, 
which may influence the early and late results of the 
chosen revascularization.
In conclusion, we would like to emphasize that the 
surgical and percutaneous procedures are complementary 
during the course of coronary artery disease. Discus­
sions between clinicians, surgeons, and interventional 
(the so­called “heart team”) are highly recommended to 
assess the advantages and disadvantages of both types 
of revascularization. Additionally, the patient and his/
her family should also be involved in the decision­
making process, and should be honestly informed about 
the available revascularization options and their risks. 
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